Brain Tumor Drugs Market Report 2026

The brain tumor drugs market size has grown strongly in recent years. It will grow from $4.03 billion in 2025 to $4.26 billion in 2026 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increasing prevalence of brain tumors, advancements in chemotherapy drugs, rising awareness about symptom management, development of hormone therapies, introduction of novel anticonvulsants.

The brain tumor drugs market size is expected to see strong growth in the next few years. It will grow to $5.5 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to growth of precision medicine, integration of ai in drug discovery, expansion of r&d in oncology, increased healthcare expenditure, rising adoption of targeted therapies. Major trends in the forecast period include personalized chemotherapy treatments, growth in hormone therapy applications, advanced pain management drugs, rising use of anticonvulsants in symptom control, expansion of brain tumor drug pipelines.

The rising number of patients undergoing chemotherapy is expected to drive the growth of the brain tumor drugs market in the coming years. Chemotherapy is a treatment that uses potent drugs to target and destroy rapidly dividing cells, including cancer cells. It serves as a primary approach for treating brain tumors, and the availability of effective chemotherapy drugs significantly influences treatment success. The effectiveness of chemotherapy is critical in extending patient survival and improving quality of life, thereby shaping the market’s development. For example, in July 2023, the Centers for Disease Control and Prevention, a US-based government agency, reported that over 1 million cancer patients in the United States receive chemotherapy or radiation annually. Consequently, the increasing number of chemotherapy patients is boosting demand for brain tumor drugs.

Key players in the brain tumor drugs market are focusing on technological innovations, such as targeted RAF kinase inhibitors, to meet the growing need for precision oncology therapies that target specific genetic mutations in brain tumors, minimizing systemic toxicity and enhancing patient outcomes. A RAF kinase inhibitor selectively blocks RAF proteins, part of the MAPK signaling pathway, to inhibit tumor cell proliferation, unlike traditional chemotherapies that non-specifically destroy rapidly dividing cells and often cause broader side effects. For instance, in November 2025, Day One Biopharmaceuticals, a US-based biotechnology company, launched OJEMDA (tovorafenib), a novel therapy for pediatric patients with relapsed or refractory low-grade gliomas harboring BRAF fusions or V600 mutations. Tovorafenib is an oral, once-weekly, brain-penetrant inhibitor that precisely targets mutant RAF proteins, providing strong central nervous system exposure and a mechanism tailored to the tumor’s molecular driver. Its features include high selectivity, reduced systemic toxicity compared with traditional chemotherapy, and suitability for pediatric patients, marking a significant advancement in genetically guided therapy for childhood brain tumors.

In September 2024, Stryker Corporation, a US-based medical technology company, acquired NICO Corporation for an undisclosed sum. Through this acquisition, Stryker aims to enhance its minimally invasive neurosurgical solutions, particularly for brain tumor removal and intracerebral hemorrhage treatment, improving patient outcomes and expanding its neurotechnology portfolio. NICO Corporation is a US-based medical device company specializing in minimally invasive neurosurgical technologies, particularly for brain tumor removal.

Major companies operating in the brain tumor drugs market are F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., CordenPharma, Eisai Co. Ltd., Emcure Pharmaceuticals Limited, Y-mAbs Therapeutics, Roche India, Novartis Oncology, Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Astellas Pharma Inc, Otsuka Pharmaceutical Co. Ltd, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, Sandoz AG, Eurofarma Laboratórios S.A., TUTEUR Argentina, The Takeda Pharmaceutical Company Limited, Pierre Fabre Group, Celnova Pharma, Pfizer S.R.L., Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Eurolab, Aspen, Adcock Ingram.

North America was the largest region in the brain tumor drugs market in 2025. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market share during the forecast period. The regions covered in the brain tumor drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the brain tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have posed challenges for the brain tumor drugs market by increasing the cost of imported active pharmaceutical ingredients and specialized formulations. The impact is particularly significant for temozolomide and bevacizumab segments, with hospital pharmacies in regions such as north america and europe facing higher procurement costs. While production costs have risen, some domestic manufacturers are leveraging tariffs to enhance local production and supply chain resilience, potentially leading to greater regional self-sufficiency and innovation in drug formulations.

The brain tumor drugs market research report is one of a series of new reports that provides brain tumor drugs market statistics, including brain tumor drugs industry global market size, regional shares, competitors with a brain tumor drugs market share, detailed brain tumor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the brain tumor drugs industry. This brain tumor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Brain tumor drugs are medications used to treat brain tumors. These include chemotherapy, hormone therapies, anticonvulsants, and painkillers. While some prescription drugs are used to manage symptoms during treatment, chemotherapy specifically targets the reduction or destruction of brain tumors.

The primary drugs for brain tumors include temozolomide, carmustine, cisplatin, bevacizumab, gefitinib, and erlotinib. Temozolomide is used to treat certain types of brain cancer, such as glioblastoma multiforme and anaplastic astrocytoma, in patients with newly diagnosed or recurrent tumors. It belongs to a class of medications known as antineoplastics (cancer drugs). Various tumor types - including medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal tumors (PNET), and others such as glioma, acoustic neuroma, and meningioma - are treated using these drugs, which are employed across hospital pharmacies, clinics, and similar healthcare settings.

The brain tumor drugs market consists of sales of Afinitor (Everolimus), Afinitor Disperz (Everolimus), Belzutifan, and Bevacizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.